AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

NASDAQ:RDNTRadNet Stock Price, Forecast & News

$17.60
-0.81 (-4.40 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$17.44
Now: $17.60
$19.16
50-Day Range
$10.16
MA: $13.82
$18.41
52-Week Range
$5.81
Now: $17.60
$23.45
Volume350,600 shs
Average Volume458,032 shs
Market Capitalization$892.23 million
P/E Ratio440.11
Dividend YieldN/A
Beta1.64
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
Read More
RadNet logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.17 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDNT
CUSIPN/A
Phone310-478-7808

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.15 billion
Cash Flow$3.28 per share
Book Value$4.09 per share

Profitability

Net Income$14.76 million

Miscellaneous

Employees8,498
Market Cap$892.23 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.

RadNet (NASDAQ:RDNT) Frequently Asked Questions

How has RadNet's stock been impacted by COVID-19 (Coronavirus)?

RadNet's stock was trading at $17.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RDNT stock has increased by 2.2% and is now trading at $17.60. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of RadNet?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for RadNet.

When is RadNet's next earnings date?

RadNet is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for RadNet.

How were RadNet's earnings last quarter?

RadNet Inc. (NASDAQ:RDNT) announced its earnings results on Monday, May, 11th. The medical research company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.16. The medical research company had revenue of $281.60 million for the quarter, compared to analyst estimates of $242.09 million. RadNet had a return on equity of 1.56% and a net margin of 0.18%. The firm's quarterly revenue was up 3.7% on a year-over-year basis. During the same period last year, the company posted ($0.08) earnings per share. View RadNet's earnings history.

What guidance has RadNet issued on next quarter's earnings?

RadNet updated its FY 2020 Pre-Market earnings guidance on Thursday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.175-1.225 billion, compared to the consensus revenue estimate of $1.2 billion.

What price target have analysts set for RDNT?

1 brokers have issued 12-month price objectives for RadNet's stock. Their forecasts range from $23.00 to $23.00. On average, they expect RadNet's share price to reach $23.00 in the next year. This suggests a possible upside of 30.7% from the stock's current price. View analysts' price targets for RadNet.

Has RadNet been receiving favorable news coverage?

Media coverage about RDNT stock has been trending extremely positive on Thursday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. RadNet earned a daily sentiment score of 4.7 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutRadNet.

Are investors shorting RadNet?

RadNet saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 1,410,000 shares, an increase of 6.0% from the April 15th total of 1,330,000 shares. Based on an average daily volume of 482,500 shares, the short-interest ratio is currently 2.9 days. Currently, 3.3% of the company's shares are sold short. View RadNet's Current Options Chain.

Who are some of RadNet's key competitors?

What other stocks do shareholders of RadNet own?

Who are RadNet's key executives?

RadNet's management team includes the following people:
  • Dr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 73)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 48)
  • Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 63)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 58)
  • Mr. Ranjan Jayanathan, Chief Information Officer & GM of Radiology Information Technology Division

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

Who are RadNet's major shareholders?

RadNet's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.45%), Beck Mack & Oliver LLC (3.74%), State Street Corp (2.58%), Global Alpha Capital Management Ltd. (2.17%), Silvercrest Asset Management Group LLC (2.00%) and Dalton Greiner Hartman Maher & Co. (1.99%). Company insiders that own RadNet stock include B Kaplan Survivor's Tru Karen, David L Swartz, Jeffrey L Linden, John V Crues, Mark Stolper, Michael L Md Sherman, Michael N Murdock and Norman R Hames. View institutional ownership trends for RadNet.

Which institutional investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Invesco Ltd., Morgan Stanley, Deutsche Bank AG, Russell Investments Group Ltd., Cheyne Capital Management UK LLP, Victory Capital Management Inc., and Victory Capital Management Inc.. Company insiders that have sold RadNet company stock in the last year include John V Crues, Mark Stolper, Michael L Md Sherman, Michael N Murdock, and Norman R Hames. View insider buying and selling activity for RadNet.

Which institutional investors are buying RadNet stock?

RDNT stock was purchased by a variety of institutional investors in the last quarter, including Beck Mack & Oliver LLC, Silvercrest Asset Management Group LLC, Dalton Greiner Hartman Maher & Co., Assenagon Asset Management S.A., Voce Capital Management LLC, Hennessy Advisors Inc., State Street Corp, and JPMorgan Chase & Co.. View insider buying and selling activity for RadNet.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $17.60.

How big of a company is RadNet?

RadNet has a market capitalization of $892.23 million and generates $1.15 billion in revenue each year. The medical research company earns $14.76 million in net income (profit) each year or $0.29 on an earnings per share basis. RadNet employs 8,498 workers across the globe.

What is RadNet's official website?

The official website for RadNet is www.radnet.com.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.